Rotavirus reassortant vaccine
AssigneesThe Wistar Institute of Anatomy and Biology, The Children's Hospital of Philadelphia
InventorsH. Fred Clark, Paul Offit, Stanley A. Plotkin
Life of this patent
Estimating the term…
Abstract
The present invention provides novel rotavirus reassortants, vaccines employing the novel reassortants and methods for their preparation and administration. One such reassortant contains the gene encoding the v.p.7 neutralization antigen of a human rotavirus. Another reassortant contains the gene encoding the v.p.4 neutralization antigen of a human rotavirus. The remaining genes are provided solely from the bovine rotavirus WC3 strain, or from both the human and bovine strains.
Claims39
Rotavirus reassortant of G1 serotype, WI79-3,9.
Rotavirus reassortant of G3 serotype, WI78-8.
Rotavirus reassortant of G2 serotype, WI79-3+WISC2-9.
Rotavirus reassortant of G4 serotype, Bricout B-9.
A vaccine useful in reducing the clinical symptoms associated with gastroenteritis caused by rotavirus infection comprising rotavirus reassortant WI79-3,9.
A rotavirus reassortant having RNA comprising a gene segment encoding viral protein (v.p.) 4 derived from a human rotavirus strain and ten gene segments derived from a human rotavirus strain and the bovine strain WC3 or progeny thereof, said reassortant suitable for use in a human vaccines, wherein at least one of said ten gene segments is derived from the bovine strain.
A vaccine useful in reducing the clinical symptoms associated with gastroenteritis caused by rotavirus infection comprising:
- (a) a first rotavirus reassortant having RNA comprising a gene segment encoding vital protein (v.p.) 4 derived from a selected human rotavirus strain and ten gene segments derived from a human rotavirus strain and bovine rotavirus strain WC3 or progeny thereof, wherein at least one of said ten gene segments is derived from the bovine rotavirus strain;
- and
- (b) a second rotavirus reassortant having RNA comprising a gene segment encoding viral protein (v.p.) 7 derived from a selected human rotavirus strain, and ten gene segments derived from a human rotavirus strain and bovine rotavirus strain WC3 or progeny thereof, wherein at least one of said ten gene segments is derived from the bovine strain;
- wherein said reassortants are suitable for use in a human vaccine.
Rotavirus reassortant WI79-4,9, deposited as American Type Culture Collection accession number VR2415.
Rotavirus reassortant WI78-1,6-11, deposited as American Type Culture Collection accession number VR2195.
A vaccine useful in reducing the clinical symptoms associated with gastroenteritis caused by rotavirus infection comprising a rotavirus reassortant selected from the group consisting of WI78-8, WI79-3+WISC2-9, and Bricout B-9.
A vaccine useful in reducing the clinical symptoms associated with gastroenteritis caused by rotavirus infection comprising:
- a rotavirus reassortant having RNA comprising a gene segment encoding vital protein (v.p.) 4 derived from a human rotavirus strain and ten gene segments derived from a human rotavirus strain and the bovine rotavirus strain WC3 or progeny thereof, said reassortant useful in a human vaccine, wherein at least one of said ten gene segments is derived from the bovine strain.
Dependencies are inferred from the claim text.